container

New Research Looks at Octreotide – A Review of Its Use in Treating Neuroendocrine Tumours

European Endocrinology, the peer-reviewed journal, publish article looking at Octreotide – A Review of Its Use in Treating Neuroendocrine Tumours.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has dramatically increased in recent years.

(PRWEB UK) 3 June 2014

European Endocrinology, the peer-reviewed journal, publish article looking at Octreotide – A Review of Its Use in Treating Neuroendocrine Tumours

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has dramatically increased in recent years. Octreotide is a somatostatin analogue used in the treatment of NETs, and its use in clinical trials has been associated with substantially increased survival. Although traditionally used for the relief of symptoms that result from release of peptides and neuroamines, there has been a growing body of evidence that suggest octreotide has antiproliferative effects. A phase III clinical study has demonstrated that the long-acting formulation (LAR), octreotide LAR, lengthens time to tumour progression in patients with well-differentiated metastatic midgut NETs, and that octreotide LAR is a treatment option for patients with metastatic midgut NETs, regardless of functional status. Furthermore, octreotide LAR has demonstrated clinical efficacy in different types of NETs. These data, along with emerging data on somatostatin analogs, may change the way doctors approach this patient population and reinforce the use of these drugs as a treatment option for patients with non-functioning tumours.

To continue reading this peer-reviewed article in full for free, please go to: http://www.touchendocrinology.com/articles/octreotide-review-its-use-treating-neuroendocrine-tumours.

Note to Editors
touchENDOCRINOLOGY (a division of Touch Medical Media) provides independent, cutting-edge, peer-reviewed content from world renowned physicians, designed to lead the debate on health and to engage, inform, and support physicians in improving patient outcomes globally.

touchENDOCRINOLOGY.com provides an international platform for peer-reviewed content from industry-leading journals alongside other carefully selected sources and aims to support physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity within the field of diabetes.

Our portfolio of peer-reviewed journals, European Endocrinology and US Endocrinology comprise of concise review articles which are designed to keep busy physicians up-to-date with the latest developments in their field and serve as a key reference resource for the international diabetes community.

http://www.touchendocrinology.com


Contact